Menu
Search
|

Menu

Close
X

Summit Therapeutics PLC SMMT.OQ (NASDAQ Stock Exchange Global Market)

11.68 USD
+0.31 (+2.73%)
As of Feb 22
chart
Previous Close 11.37
Open 11.39
Volume 4,218
3m Avg Volume 14,537
Today’s High 11.68
Today’s Low 11.39
52 Week High 16.59
52 Week Low 8.80
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.57 Mean rating from 7 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Frank Armstrong
Non-Executive Chairman of the Board, Since 2013
Salary: £50,000.00
Bonus: --
Glyn Edwards
Chief Executive Officer, Executive Director, Since 2012
Salary: £330,000.00
Bonus: --
Erik Ostrowski
Chief Financial Officer, Since 2014
Salary: --
Bonus: --
David Roblin
Chief Operating Officer, President - Research and Development, Since 2017
Salary: --
Bonus: --
Ralf Rosskamp
Chief Medical Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

136A Eastern Avenue, Milton Park
ABINGDON     OX14 4SB

Phone: +441235.443939

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

SPONSORED STORIES